New drug combo identified for liver cancer via CRISPR-Cas9 screen
A research team has successfully repurposed an approved drug ifenprodil, a vasodilator, to be used in combination with the FDA-approved first-line drug sorafenib for hepatocellular carcinoma (HCC) treatment. This study leveraged on their CombiGEM-CRISPR v2.0 screening platform1 to expedite the search among the many possible drug combinations to inhibit druggable targets in the genome for treating HCC.
Materials provided by The University of Hong Kong. Note: Content may be edited for style and length.
Source link aaaaa